Journey Medical (Journey Medical) EBIT : $-2.34 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Journey Medical EBIT?

Journey Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-9.89 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.34 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Journey Medical's annualized ROC % for the quarter that ended in Mar. 2024 was -132.99%. Journey Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -43,973.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Journey Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -3.73%.

Journey Medical EBIT Historical Data

The historical data trend for Journey Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical EBIT Chart

Journey Medical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

5.26

7.85

-35.33

-27.55

-1.93

Journey Medical Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial												-9.49	-7.61	17.15	-1.99	-9.89

Competitive Comparison of Journey Medical's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Journey Medical's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Journey Medical's EV-to-EBIT falls into.

Journey Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.34 Mil.

Journey Medical (NAS:DERM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Journey Medical's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-40.36 * ( 1 - 0% )	/	( (31.11	+	29.587)	/ 2 )
=	-40.36	/	30.3485
=	-132.99 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	76.849	-	31.152	-	( 27.439	-	max(0, 41.868	-	56.455	+	27.439	))
=	31.11

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	66.571	-	28.907	-	( 24.057	-	max(0, 38.936	-	47.013	+	24.057	))
=	29.587

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Journey Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-39.576	/	( ( (0.101 + max(-12.753, 0))	+	(0.079 + max(-15.896, 0)) )	/	2 )
=	-39.576	/	( ( 0.101	+	0.079 )	/	2 )
=	-39.576	/	0.09
=	-43,973.33 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(15.222	+	10.206	+	3.588)	-	(31.152	+	0	+	10.617)
=	-12.753

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(9.799	+	10.58	+	2.577)	-	(28.907	+	0	+	9.945)
=	-15.896

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Journey Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-2.342	/	62.757
	=	-3.73 %

Journey Medical EBIT Related Terms

Thank you for viewing the detailed overview of Journey Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Journey Medical (Journey Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258

Website

https://www.journeymedicalcorp.com

Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.

Executives

Jeffrey Paley	director	C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith	director	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Claude Maraoui	director, officer: President & CEO	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch	officer: Interim CFO	C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert	officer: Chief Financial Officer	4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135